Paul - evidence is strongly mounting support your comments from complimentary sources. In a type of concurrence with importance of PS blockade - except across its receptors on the T-Cell side of things.
Many are aware that TIM-3 and LAG-3 are two of several checkpoints that bind to PS. Not sure how many are aware that the rate of clinical trials evaluating these two checkpoint inhibitors is rising, and that multiple smaller scale trials are showing great results using that combo. That is driving the greater investment and expansion of trials.
Why is that a good thing? All these combo trials are conducted by large pharma companies who are seeing supporting signals to increase investment.
Peregrine holds the molecule that achieves the complimentary results (blocking at PS site) holistically and without having to chase a multitude of checkpoints that bind to PS to stop/reduce immune response.
BP's excitement about TIM-3 and LAG-3 should be a very good cause for upbeat expectations from bavituximab, and a likely reason that world-class institutions and AZN are in the game. The beauty is having a single solution that blocks PS, vs. possibly dozens that block the several other T-Cell checkpoints with which it binds.
Commercially, clinically and logistically, there is no better winner in this competition if one can do the work of many. Provided this mechanism works and is shown to do what so many diverse professionals seem to be suggesting - its becoming a game of timing and finesse.
The more good news I hear from Industry on TIM-3 and LAG-3, the happier I get. Definitely happier now than 12 months ago.
Best,
MH
News 
Market Data 
Discover 
AI
